• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2016 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2016 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

    Thumbnail
    URI
    http://hdl.handle.net/11287/619940
    Author
    Singh, D.
    Roche, N.
    Halpin, David M
    Agusti, A.
    Wedzicha, J. A.
    Martinez, F. J.
    Date
    2016-09-01
    Journal
    American journal of respiratory and critical care medicine
    Type
    Journal Article
    Publisher
    American Thoracic Society
    DOI
    10.1164/rccm.201606-1179PP
    Rights
    Archived with thanks to American journal of respiratory and critical care medicine
    Metadata
    Show full item record
    Abstract
    Clinical phenotyping is currently used to guide pharmacological treatment decisions in chronic obstructive pulmonary disease (COPD), a personalized approach to care. Precision medicine integrates biological (endotype) and clinical (phenotype) information for a more individualized approach to pharmacotherapy, to maximize the benefit versus risk ratio. Biomarkers can be used to identify endotypes. To evolve toward precision medicine in COPD, the most appropriate biomarkers and clinical characteristics that reliably predict treatment responses need to be identified. FEV1 is a marker of COPD severity and has historically been used to guide pharmacotherapy choices. However, we now understand that the trajectory of FEV1 change, as an indicator of disease activity, is more important than a single FEV1 measurement. There is a need to develop biomarkers of disease activity to enable a more targeted and individualized approach to pharmacotherapy. Recent clinical trials testing commonly used COPD treatments have provided new information that is likely to influence pharmacological treatment decisions both at initial presentation and at follow up. In this Perspective, we consider the impact of recent clinical trials on current COPD treatment recommendations. We also focus on the movement toward precision medicine and propose how this field needs to evolve in terms of using clinical characteristics and biomarkers to identify the most appropriate patients for a given pharmacological treatment.
    Citation
    Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. 2016, 194 (5):541-9 Am. J. Respir. Crit. Care Med.
    Publisher URL
    http://www.atsjournals.org/doi/abs/10.1164/rccm.201606-1179PP?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
    Collections
    • 2016 RD&E publications
    • Respiratory Medicine

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2021  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV